- Rheumatologie-App Injektionstechnik
- Neue Studien
- Kongress Highlights
- EULAR 2019
- EULAR 2018
- EULAR 2017
- EULAR 2016
- EULAR 2015
- EULAR 2014
- ACR 2019
- ACR 2018
- ACR 2017
- ACR 2015
- ACR 2014
- Rheuma Top 2019
- Rheuma Top 2018
- Rheuma Top 2017
- Rheuma Top 2015
- Rheuma Top 2014
- Bilddatenbank
- RheumaTool
- SlideSet RA
- SlideSetSpA
- SonoTool
- FOCUS «Der Fuss»
- FOCUS «Die Hand»
- FOCUS «Kinderrheumatologie»
- EisenPaket
- LupusPaket
- OsteoPaket
- Publikationen
- Literaturservice
- Richtlinien
- Schmerzpaket
- Immunotalk
ACR 2019 | Daily Highlights
Sequential TNF inhibitors for PsA?
DOES DRUG EFFECTIVENESS OF 2ND AND 3RD TNF INHIBITORS IN PATIENTS WITH PSORIATIC ARTHRITIS DEPEND ON THE REASON FOR WITHDRAWAL FROM THE PREVIOUS TREATMENT? RESULTS FROM THE EUROSPA RESEARCH COLLABORATION.
Abstract: 1088
Authors: Cecilie Heegaard Brahe et al.
Key content:
Patients with PsA may stop treatment with a first TNF inhibitor because of adverse events (AE) or lack of effect (LOE). Previously, the EuroSpA Collaboration (collecting data from PsA patients in routine care from 12 European registries) has demonstrated a one-year retention rate of 77% for the first TNF inhibitor and a 6 months LUNDEX adjusted DAS28 remission rate of 45%. 4971 patients started on their 2nd and 1768 patients on their 3rd TNF inhibitor showing overall retention rates of 69% and 66%, regardless of the reason why the 1st TNF inhibitor was stopped. LUNDEX adjusted DAS28 remission rates after 6 months were 35% and 27% for the 2nd and 3rd TNF inhibitor.
Relevance:
Retention and remission rates are decreased with an increasing number of TNF inhibitors in patients with active psoriatic arthritis-similar to data observed in RA cohorts. Interestingly, the reason for stopping the previous anti-TNF did not significantly impact outcome.
Zusammenfassung und Kommentar von:
Prof. Dr. A. Rubbert-Roth
St. Gallen
